Antonio Bertoletti (MD) is an expert in the field of viral hepatitis, with a specific interest in the immunopathogenesis of HBV infection. During his MD (1991), he spent two years at The Scripps Research Institute (La Jolla) characterizing for the first time the Hepatitis B virus (HBV) specific cytotoxic T cell response in man. He worked in the Department of Infectious Diseases, the University of Parma until 1997 before accepting a position of Senior Lecturer at “The UCL Institute of Hepatology (UK)”. 

In 2006 he became the Director of Infection and Immunity Program at the Singapore Institute for Clinical Sciences (A*STAR) until 2013 before moving, as Full Professor, at the Emerging Viral Disease Program at Duke-NUS Medical School.

In 2015 he founded Lion TCR Pte, a biotech company developing immune-based treatments for virus-related cancers and chronic viral infections.

His current research is focus on the development of new immunological based therapies (TCR-redirected T cells) for the treatment of HBV chronic infection and Hepatocellular carcinoma. In the last 6 months, after the start of the COVID-19  pandemic, his laboratory has been actively involved in the characterization of SARS-COV2 specific T cell immune response.